{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:28:12Z","timestamp":1785407292409,"version":"3.56.0"},"posted":{"date-parts":[[2025,9,5]]},"group-title":"Cancer Biology","reference-count":65,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA214274"],"award-info":[{"award-number":["R01CA214274"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["MCL700118"],"award-info":[{"award-number":["MCL700118"]}],"id":[{"id":"https:\/\/ror.org\/04m0xav37","id-type":"ROR","asserted-by":"publisher"}]},{"award":["RS-2024-00411768"],"award-info":[{"award-number":["RS-2024-00411768"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["RS-2024-00414906"],"award-info":[{"award-number":["RS-2024-00414906"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Resistance to Bruton\u2019s tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies, limiting treatment durability. Here, we identify ferroptosis suppression as a central mechanism of BTKi resistance in mantle cell lymphoma (MCL). Aberrant BRG1 activity protects cells from BTKi-induced ferroptosis by restricting reactive oxygen species (ROS) and labile iron. Mechanistically, BRG1 promotes resistance through both BTK-dependent survival signaling and a BTK-independent transcriptional program. The latter is mediated by BRG1-driven induction of MEF2B, which upregulates NDUFA4L2 to inhibit mitochondrial respiration, thereby blocking mitochondria-dependent ferroptosis. Pharmacologic inhibition of BRG1 disrupts these programs, restoring ferroptotic sensitivity and synergizing with BTKi across resistant MCL models. Together, these findings establish BRG1 as a central regulator of therapy resistance and provide a rationale for co-targeting BRG1 and BTK as a therapeutic strategy for B-cell malignancies.<\/jats:p>","DOI":"10.1101\/2025.09.02.673601","type":"posted-content","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:10:13Z","timestamp":1757074213000},"source":"Crossref","is-referenced-by-count":0,"title":["Leveraging BRG1 Driven Ferroptosis Resistance to Overcome Treatment Resistance"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-5777","authenticated-orcid":false,"given":"Soo-Yeon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"Nikolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belem","family":"Yoval-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sieun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Gribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inah","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"DiLiberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojoong","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2202","authenticated-orcid":false,"given":"Jihye","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025090900000766000_2025.09.02.673601v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2025090900000766000_2025.09.02.673601v1.2","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","year":"2022","journal-title":"Blood"},{"key":"2025090900000766000_2025.09.02.673601v1.3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","year":"2022","journal-title":"Blood"},{"key":"2025090900000766000_2025.09.02.673601v1.4","first-page":"3137","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders","volume":"141","year":"2023","journal-title":"Blood"},{"key":"2025090900000766000_2025.09.02.673601v1.5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/10781552231216886","article-title":"Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma","volume":"30","year":"2024","journal-title":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners"},{"key":"2025090900000766000_2025.09.02.673601v1.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"2025090900000766000_2025.09.02.673601v1.7","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"2025090900000766000_2025.09.02.673601v1.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"2025090900000766000_2025.09.02.673601v1.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006783"},{"key":"2025090900000766000_2025.09.02.673601v1.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"2025090900000766000_2025.09.02.673601v1.11","doi-asserted-by":"crossref","first-page":"102131","DOI":"10.1016\/j.eclinm.2023.102131","article-title":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study","volume":"62","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025090900000766000_2025.09.02.673601v1.12","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","year":"2019","journal-title":"The Lancet. Haematology"},{"key":"2025090900000766000_2025.09.02.673601v1.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4842"},{"key":"2025090900000766000_2025.09.02.673601v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"2025090900000766000_2025.09.02.673601v1.15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","year":"2021","journal-title":"Journal of hematology & oncology"},{"key":"2025090900000766000_2025.09.02.673601v1.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"key":"2025090900000766000_2025.09.02.673601v1.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-886457"},{"key":"2025090900000766000_2025.09.02.673601v1.18","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1080\/10428194.2019.1612062","article-title":"A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma","volume":"60","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025090900000766000_2025.09.02.673601v1.19","first-page":"3067","volume":"124","year":"2014","journal-title":"Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma"},{"key":"2025090900000766000_2025.09.02.673601v1.20","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","year":"2003","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2025090900000766000_2025.09.02.673601v1.21","doi-asserted-by":"crossref","unstructured":"Lee, C. , Huang, X. , Di Liberto, M. , Martin, P. & Chen-Kiang, S . Targeting CDK4\/6 in mantle cell lymphoma. Annals of lymphoma 4(2020).","DOI":"10.21037\/aol.2019.12.01"},{"key":"2025090900000766000_2025.09.02.673601v1.22","doi-asserted-by":"crossref","unstructured":"Burkart, M. & Karmali, R . Relapsed\/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. Journal of personalized medicine 12(2022).","DOI":"10.3390\/jpm12030376"},{"key":"2025090900000766000_2025.09.02.673601v1.23","doi-asserted-by":"crossref","unstructured":"Zhang, L. , et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science translational medicine 11(2019).","DOI":"10.1126\/scitranslmed.aau1167"},{"key":"2025090900000766000_2025.09.02.673601v1.24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","year":"2019","journal-title":"Nature reviews. Clinical oncology"},{"key":"2025090900000766000_2025.09.02.673601v1.25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-023-01736-8","article-title":"SWI\/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities","volume":"22","year":"2023","journal-title":"Molecular cancer"},{"key":"2025090900000766000_2025.09.02.673601v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.032"},{"key":"2025090900000766000_2025.09.02.673601v1.27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41591-018-0019-5","article-title":"Mutations in the SWI\/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer","volume":"24","year":"2018","journal-title":"Nature medicine"},{"key":"2025090900000766000_2025.09.02.673601v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7580"},{"key":"2025090900000766000_2025.09.02.673601v1.29","doi-asserted-by":"crossref","first-page":"114345","DOI":"10.1016\/j.celrep.2024.114345","article-title":"CRISPR activation screens identify the SWI\/SNF ATPases as suppressors of ferroptosis","volume":"43","year":"2024","journal-title":"Cell reports"},{"key":"2025090900000766000_2025.09.02.673601v1.30","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/s41467-020-19402-8","article-title":"Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients","volume":"11","year":"2020","journal-title":"Nature Communications"},{"key":"2025090900000766000_2025.09.02.673601v1.31","doi-asserted-by":"publisher","DOI":"10.1002\/path.4633"},{"key":"2025090900000766000_2025.09.02.673601v1.32","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0433"},{"key":"2025090900000766000_2025.09.02.673601v1.33","doi-asserted-by":"publisher","DOI":"10.1101\/gad.232710.113"},{"key":"2025090900000766000_2025.09.02.673601v1.34","first-page":"434","volume":"601","year":"2022","journal-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer"},{"key":"2025090900000766000_2025.09.02.673601v1.35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","year":"2020","journal-title":"Nature reviews. Clinical oncology"},{"key":"2025090900000766000_2025.09.02.673601v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.02.011"},{"key":"2025090900000766000_2025.09.02.673601v1.37","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/bcj.2015.89","article-title":"Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas","volume":"5","year":"2015","journal-title":"Blood cancer journal"},{"key":"2025090900000766000_2025.09.02.673601v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/nature11378"},{"key":"2025090900000766000_2025.09.02.673601v1.39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41408-025-01333-6","article-title":"The SOX11:SMARCA4 complex is a driver of oncogenic transcriptional programs in mantle cell lymphoma","volume":"15","year":"2025","journal-title":"Blood cancer journal"},{"key":"2025090900000766000_2025.09.02.673601v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0243-z"},{"key":"2025090900000766000_2025.09.02.673601v1.41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920"},{"key":"2025090900000766000_2025.09.02.673601v1.42","doi-asserted-by":"publisher","DOI":"10.1101\/gad.872801"},{"key":"2025090900000766000_2025.09.02.673601v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80040-0"},{"key":"2025090900000766000_2025.09.02.673601v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.08.006"},{"key":"2025090900000766000_2025.09.02.673601v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.10.008"},{"key":"2025090900000766000_2025.09.02.673601v1.46","doi-asserted-by":"crossref","unstructured":"Chen, X. , Yu, C. , Kang, R. & Tang, D . Iron Metabolism in Ferroptosis. Volume 8 - 2020(2020).","DOI":"10.3389\/fcell.2020.590226"},{"key":"2025090900000766000_2025.09.02.673601v1.47","doi-asserted-by":"crossref","unstructured":"Lins, F.V. , et al. Ibrutinib Modulates Proliferation, Migration, Mitochondrial Homeostasis, and Apoptosis in Melanoma Cells. Biomedicines 12(2024).","DOI":"10.3390\/biomedicines12051012"},{"key":"2025090900000766000_2025.09.02.673601v1.48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","article-title":"BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy","volume":"143","year":"2022","journal-title":"Acta neuropathologica"},{"key":"2025090900000766000_2025.09.02.673601v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.10.042"},{"key":"2025090900000766000_2025.09.02.673601v1.50","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-24-3790","article-title":"A Phase I Study of FHD-286, a Dual BRG1\/BRM (SMARCA4\/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies","volume":"31","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2025090900000766000_2025.09.02.673601v1.51","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2023-178090","article-title":"Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1\/BRM (SMARCA4\/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies","volume":"142","year":"2023","journal-title":"Blood"},{"key":"2025090900000766000_2025.09.02.673601v1.52","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","year":"2023","journal-title":"Blood"},{"key":"2025090900000766000_2025.09.02.673601v1.53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1962"},{"key":"2025090900000766000_2025.09.02.673601v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08974-4"},{"key":"2025090900000766000_2025.09.02.673601v1.55","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2688"},{"key":"2025090900000766000_2025.09.02.673601v1.56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314608110"},{"key":"2025090900000766000_2025.09.02.673601v1.57","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1080\/10428194.2021.1933480","article-title":"Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets","volume":"62","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2025090900000766000_2025.09.02.673601v1.58","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.xcrm.2024.101484","article-title":"Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma","volume":"5","year":"2024","journal-title":"Cell Reports Medicine"},{"key":"2025090900000766000_2025.09.02.673601v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06409-6"},{"key":"2025090900000766000_2025.09.02.673601v1.60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ccell.2024.02.010","article-title":"ARID1A orchestrates SWI\/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis","volume":"42","year":"2024","journal-title":"Cancer cell"},{"key":"2025090900000766000_2025.09.02.673601v1.61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41467-019-13989-3","article-title":"Modeling medulloblastoma in vivo and with human cerebellar organoids","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2025090900000766000_2025.09.02.673601v1.62","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","article-title":"Chromatin accessibility profiling by ATAC-seq","volume":"17","year":"2022","journal-title":"Nature protocols"},{"key":"2025090900000766000_2025.09.02.673601v1.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2025090900000766000_2025.09.02.673601v1.64","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac935"},{"key":"2025090900000766000_2025.09.02.673601v1.65","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAC194"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.02.673601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:29:53Z","timestamp":1768469393000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.09.02.673601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1101\/2025.09.02.673601","relation":{},"subject":[],"published":{"date-parts":[[2025,9,5]]},"subtype":"preprint"}}